Psylutions

Leading the industry in regulated data-backed natural medicine focused on patient population specific pharmacological signatures for optimized outcomes

[Psylutions @PsylutionsNow]

What Trauma-Informed Psilocybin Care Really Looks Like with Rhonda DeSantis https://t.co/XY8pmAd7Kp via @YouTube

[Steve @Waracken]

Ahead of schedule

Happy to see they were able to maintain the Q4 timeline for the data

$HELP

$ATAI $DFTX $GHRS $CMPS $ENP

[Psychedelic Alpha @Psyched_Alpha]

Following a series of announcements earlier this week, the U.S. Food and Drug Administration (FDA) homepage now features the agency's work in "Advancing Research on Psychedelic Drugs'.

[Psychedelic Alpha @Psyched_Alpha]

“Once it’s submitted, it obviously gives the FDA an opportunity to respond to what we have, and that’s going to give us a clearer picture of what’s required”, Suzuki explained. “Best case scenario they approve it right away,” he went on, “worst case scenario they put it on hold and request additional preclinical testing.” - Joji Suzuki

Read the full conversation on our website: https://t.co/8mjAqAZBtN

[Psymposia @psymposia]

Billionaire SpaceX investor Steve Jurvetson accused Psymposia of being "funded by Big Pharma" to pressure FDA approval of botched MDMA trials.

Today, he congratulates Atai—backed by fellow tech billionaire Peter Thiel—on its acquisition by the world’s largest pharma company.

[Brian Barnett @BrianBarnettMD]

Using NSDUH data, we found that prevalence of repeat use of LSD drops off pretty quickly over time after first use. Pretty interesting phenomenon for a compound that can induce transformative experiences for some. https://t.co/VVAuxEhS5v

[Definium Therapeutics @definiumtx]

Big news in mental health! @JAMA_current published results from MindMed’s Phase 2b study of MM120 (lysergide D-tartrate) in generalized anxiety disorder (GAD) – the first randomized controlled trial of its kind for LSD in psychiatry.

More than 60 million Americans live with GAD and major depressive disorder (MDD), and far too many still struggle to find relief with existing treatments. These results mark a major milestone for psychedelic medicine and highlight the powerful potential of a new treatment option.

This isn’t just data — it’s a step toward a new era in psychiatry. We’re proud to lead the way.
Learn more: https://t.co/wPHrooL5zd

#MentalHealth #Psychedelics #ScienceMatters

[Matthew W. Johnson @Drug_Researcher]

Just published: our RCT shows psilocybin (magic mushrooms) dramatically beats nicotine patch for quitting smoking using the same psychotherapy! A single psilocybin session showed 6x greater odds of staying quit. Biologically verified. In @JAMANetworkOpen Thread 🧵 #Psychedelics #QuitSmoking

[Christian Angermayer @C_Angermayer]

https://t.co/b4x7i8vnyv

[Psychedelic Alpha @Psyched_Alpha]

Shares in Definium Therapeutics $DFTX climb over 50 % on positive Phase 3 topline data

Other psychedelic drug developers rise modestly

[Psychedelic Vantage @PsychedVantage]

New Frontiers in Psychedelic Research: Iboga Microdosing with Dr. @burtontabaac & Teresa Yung

https://t.co/lpWcBdt9Hy

[Psychedelic Vantage @PsychedVantage]

Psilera Debuts Novel Synthetic Platform to Aid Discovery of Neuroplastogens in New Publication

https://t.co/1QDse0CNAK

[Shining Science @ShiningScience]

Researchers just found common genes linking 8 major mental health issues — to including autism, ADHD, schizophrenia, bipolar disorder, major depressive disorder, Tourette syndrome, obsessive-compulsive disorder, and anorexia.

These disorders all share common genetic variants that influence brain development.
Researchers found that these genetic differences impact multiple stages of brain growth and are involved in complex protein interactions. This discovery could explain why many of these conditions often appear together in individuals and families, offering a fresh perspective on mental health connections.

By identifying 683 genetic variants that regulate brain development, scientists hope to pave the way for new treatments targeting these shared genetic factors. This research challenges traditional classifications of psychiatric disorders and suggests that a single therapy could potentially address multiple conditions. With nearly 1 billion people worldwide affected by mental health disorders, these findings mark a significant step toward more effective, genetically-informed treatments.

[Street Stocker @streetstocker]

If rec gets pulled into S3, the MSO model changes fast. Stocks behaving like even medical will get rolled back. The clock starts on Monday.

Good luck to all.

$MSOS $CURLF $TRLV $GTBIF

[Johns Hopkins Psychedelic Research Center @JHPsychedelics]

CPCR Associate Professor Dr. David Yaden was interviewed in an article with the Atlantic, providing insights on the safety, efficacy, and opportunities for psychedelic studies: https://t.co/w3MTYJQ0xY

[Chris Palmer, MD @ChrisPalmerMD]

@JeromeAdamsMD The heartbreaking piece of this for me as a psychiatrist is knowing that heavy marijuana use is associated with a dramatic increase in the risk for psychosis.

"Chillaxing" can turn into a life sentence of a chronic psychotic disorder.
https://t.co/udjmErFD0R

[Julie Holland, MD @BellevueDoc]

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats

https://t.co/In0U5fQ9Cb

[Johns Hopkins Psychedelic Research Center @JHPsychedelics]

CPCR Associate Director Dr. Albert Garcia-Romeu weighed in on a recent case report of psilocybin administration for an individual with suspected Alzheimer's Disease, noting some important concerns about the report: “We currently have no rigorous evidence for clinical benefits of psilocybin or other psychedelics in patients with dementia and need to proceed accordingly until we have more data.��
https://t.co/ssomPxaZpl

[JAMA Psychiatry @JAMAPsych]

This narrative review suggests mental disorders are statistical clusters of biopsychosocial properties, not sharply defined categories, mirroring concepts in species classification and supporting dimensional #MentalHealth frameworks. https://t.co/SfES3sUTlh

[Psylutions @PsylutionsNow]

Meanwhile precision dosed natural Psilocybin had been having immediate and lasting benefits in MDD.

[Psychedelic Vantage @PsychedVantage]

Neumora scraps depression drug development after repeated trial failures

$NMRA

https://t.co/YJd1ywI9s0